ArticleEndoscopy international open2026
All-cause mortality, adverse events and associated factors following endoscopic retrograde cholangiopancreatography for benign indications in England.
Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Population-based data on outcomes of endoscopic retrograde cholangiopancreatography (ERCP) for benign indications are limited. We examined the impact of changing patient demographics on ERCP outcomes. Patients and methods: Adults undergoing first ERCP for benign indications between 2003 and 2020 in England were identified in Hospital Episode Statistics. All-cause mortality within 30 days and adverse event rates within 7 days were calculated. Multivariable logistic regression analysis explored factors associated with all-cause mortality. Results: A total of 283,972 patients were included; 63.4% female; median age 67 years (interquartile range 50-79). Twenty-five percent of ERCPs in 2019/2020 were performed in patients with a Charlson comorbidity score ≥ 5, compared with 8% in 2003/2004. Three percent of patients who underwent day case ERCP had an emergency readmission with pancreatitis. Thirty-day all-cause mortality fell by 31% over the study period. Mortality was associated with age (age quintile ≥ 82 years; odds ratio 19.22; 95% confidence interval [CI] 15.59-23.69 compared with 18-46 years), male sex (1.21; CI 1.14-1.27), Black or Black British ethnicity (1.42; CI 1.07-1.90), increasing comorbidity score ≥ 5 (3.35; CI 3.14-3.57), and increasing provider annual ERCP volume (volume ≥ 151; 1.08; CI 1.01-1.16). Elective ERCP (0.30; CI 0.28-0.33) and those in recent years were associated with lower mortality (2019/2020 compared with 2003/2004 (0.40; CI 0.34-0.48). Statistically significant variations in 30-day all-cause mortality were observed between ERCP providers. Conclusions: Despite the increasing age and comorbidities of patients undergoing ERCP for benign indications, 30-day all-cause mortality fell by 31% in recent years. All-cause mortality was associated with age, males, comorbidities, black ethnicity, emergency ERCP, and increasing provider volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.